Truist Financial Corp Buys 3,381 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Truist Financial Corp lifted its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 92.1% during the second quarter, Holdings Channel.com reports. The firm owned 7,054 shares of the medical instruments supplier’s stock after acquiring an additional 3,381 shares during the period. Truist Financial Corp’s holdings in LeMaitre Vascular were worth $580,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Driehaus Capital Management LLC boosted its position in shares of LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after purchasing an additional 90,573 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of LeMaitre Vascular by 5.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,469 shares of the medical instruments supplier’s stock worth $861,000 after purchasing an additional 583 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of LeMaitre Vascular by 68.6% during the 2nd quarter. AQR Capital Management LLC now owns 22,569 shares of the medical instruments supplier’s stock worth $1,857,000 after purchasing an additional 9,183 shares in the last quarter. Alpha DNA Investment Management LLC bought a new position in shares of LeMaitre Vascular during the 2nd quarter worth about $499,000. Finally, Public Sector Pension Investment Board lifted its position in LeMaitre Vascular by 8.3% in the 2nd quarter. Public Sector Pension Investment Board now owns 43,999 shares of the medical instruments supplier’s stock valued at $3,620,000 after acquiring an additional 3,379 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $91.24 on Wednesday. The firm has a 50-day moving average price of $88.42 and a two-hundred day moving average price of $81.05. LeMaitre Vascular, Inc. has a 52 week low of $44.27 and a 52 week high of $93.32. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of 60.42, a price-to-earnings-growth ratio of 2.45 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The company had revenue of $55.85 million during the quarter, compared to analyst estimates of $54.98 million. During the same quarter last year, the business posted $0.37 EPS. LeMaitre Vascular’s quarterly revenue was up 11.4% compared to the same quarter last year. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, August 29th. Investors of record on Thursday, August 15th were paid a $0.16 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $0.64 dividend on an annualized basis and a yield of 0.70%. LeMaitre Vascular’s dividend payout ratio is 42.38%.

Insider Activity at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.79% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on LMAT shares. Barrington Research reaffirmed an “outperform” rating and issued a $92.00 price target on shares of LeMaitre Vascular in a research report on Friday, September 20th. JMP Securities raised their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. Lake Street Capital started coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target on the stock. Finally, Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research report on Tuesday. They issued a “neutral” rating and a $96.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $94.67.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.